abs133.txt	cervical	cancer	is	currently	the	fourth	leading	cause	of	cancer	death	among	womenworldwide		with	most	cases	occurring	in	low-	and	middle-income	countries		safe	highly	effective	vaccines	against	hpv	have	been	on	the	market	since	2006		yetonly	6%	of	girls	worldwide	have	received	this	life-saving	cancer	preventionintervention		international	organizations		including	path		gavi		and	thepharmaceutical	companies	merck	and	glaxosmithkline		have	provided	support	toeligible	low-	and	middle-income	countries	to	implement	national	hpv	vaccinationprograms		still		glaring	disparities	in	the	availability	of	national	hpvvaccination	programs	and	the	coverage	of	the	primary	target	population	betweenthe	global	north	and	south	persist		we	illustrate	worldwide	hpv	vaccineimplementation	and	coverage	using	an	online	data	visualization		which	is	publiclyavailable	and	can	be	used	to	gain	unique	insights		we	also	present	three	emergingsolutions	to	transform	future	hpv	vaccine	delivery	in	low-	and	middle-incomecountries		low-cost	generics		single-dose	vaccination		and	co-administration	withother	adolescent	vaccines		by	rapidly	expanding	access	to	hpv	vaccination	togirls	everywhere		vaccine-type	hpv	infections	can	be	virtually	eliminated		athigh	vaccination-coverage	levels		more	than	80%-or	approximately	230	000-of	thecervical	cancer	deaths	that	occur	each	year	can	be	averted	
